Ep190: Neil Kumar on Building a Rare Disease Drug Company

What It Covers

Neil Kumar, founder and CEO of BridgeBio Pharma, details how he built a rare disease drug company using a hub-and-spoke portfolio model starting in 2015 with $7M. The company now has one blockbuster drug generating $108M in a single quarter, with two additional programs showing strong phase three clinical results.

Key Questions Answered

• •Hub-and-Spoke Portfolio Design: BridgeBio structures each drug program as a separate subsidiary with its own focused disease team, while centralizing regulatory, manufacturing, legal, and finance functions. This variabilizes fixed costs and allows capital reallocation toward programs that work. The model enables disease-specific scientific focus and incentive alignment without duplicating overhead across every program, keeping per-program spend well under $250M from discovery through approval.
• •Biology-First Asset Selection: Rather than starting with a technology platform and finding diseases to fit it, BridgeBio works backward from well-characterized Mendelian conditions where genotype-to-phenotype connections are quantitatively predictable. Programs must meet three criteria simultaneously: high probability of technical success, positive net present value, and a credible path to first-or-best-in-class status. This filters out scientifically ambiguous bets before capital is committed.
• •Stabilization Potency Predicts Clinical Outcomes: Across four independent clinical experiments in TTR amyloidosis, every incremental improvement in protein stabilization or knockdown percentage produced proportionally better patient outcomes. Tafamidis at 35% stabilization produced weak results; inotersen at 70% knockdown performed better; Alnylam's 84% knockdown performed better still. Acoramidis achieves 90%+ stabilization, which predicted its 42% reduction in combined hospitalization and death at 30 months.
• •Debt Financing Before Revenue Is Viable but Carries Equity Perception Risk: BridgeBio raised over $1 billion in convertible debt before having any revenue-generating product, using portfolio diversification to satisfy debt investors who evaluated the full pipeline rather than a single asset. This cash reserve allowed the company to survive a failed interim endpoint and complete its phase three trial. However, traditional biotech equity investors penalized the stock disproportionately due to aversion to leverage on pre-revenue companies.
• •Surrogate Endpoints Can Mislead in Evolving Standard-of-Care Environments: BridgeBio's phase three interim analysis failed on six-minute walk distance because background standard-of-care improvements—better diuresis protocols and increased SGLT2 inhibitor use—prevented placebo patients from declining as historical data predicted. The lesson: when designing trials in disease areas where supportive care is actively improving, surrogate endpoint assumptions based on older natural history data may underestimate placebo arm stability, requiring longer trials with hard endpoints like mortality and hospitalization.
• •Focus on Process Metrics, Not Outcome Metrics, in Drug Development: Because drug development is net-negative expected return on any individual program, leaders who personalize failures become less effective. Kumar recommends explicitly writing down process quality indicators—experimental rigor, decision criteria, capital allocation discipline—and evaluating performance against those rather than binary trial outcomes. Maintaining a mentor network focused on patient impact rather than stock price provides psychological stability during multi-year downturns between data readouts.